IQVIA (NYSE:IQV) Insider Sells 4,446 Shares of Company Stock

IQVIA Holdings Inc. (NYSE:IQV) insider Eric Sherbet sold 4,446 shares of the company’s stock in a transaction on Monday, November 9th. The stock was sold at an average price of $278.83, for a total value of $1,239,678.18. Following the transaction, the insider directly owned 24,989 shares in the company, valued at approximately $6,967,682.87. The trade was a 15.10% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link.

IQVIA Stock Down 1.2%

Shares of IQVIA stock traded down $3.42 during trading on Thursday, reaching $271.11. The company’s stock had a trading volume of 1,041,118 shares, compared to its average volume of 1,427,896. The company has a quick ratio of 0.83, a current ratio of 0.83 and a debt-to-equity ratio of 2.18. The company has a market cap of $44.68 billion, a price-to-earnings ratio of 23.71, a P/E/G ratio of 2.44 and a beta of 1.16. IQVIA Holdings Inc. has a 1-year low of $154.50 and a 1-year high of $284.50. The company has a 50-day simple moving average of $267.67 and a two-hundred day simple moving average of $211.75.

IQVIA (NYSE:IQV) last announced its earnings results on Tuesday, October 27th. The medical research company reported $3.34 earnings per share for the quarter, topping the consensus estimate of $3.26 by $0.08. IQVIA had a return on equity of 30.02% and a net margin of 8.05%. The firm had revenue of $4.43 billion for the quarter, compared to the consensus estimate of $4.37 billion. During the same period in the previous year, the business earned $3.00 EPS. The firm’s revenue for the quarter was up 8.0% on a year-over-year basis. As a group, equities analysts forecast that IQVIA Holdings Inc. will post 11.53 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the stock. HSBC lifted their target price on shares of IQVIA from $280.00 to $300.00 and gave the stock a “buy” rating in a research note on Tuesday, September 1st. UBS Group started coverage on shares of IQVIA in a research note on Wednesday, September 30th. They set a “buy” rating and a $345.00 price target on the stock. Royal Bank Of Canada lifted their price objective on shares of IQVIA from $247.00 to $319.00 and gave the stock an “outperform” rating in a research note on Tuesday, September 29th. Jefferies Financial Group lifted their price objective on shares of IQVIA from $220.00 to $290.00 and gave the stock a “buy” rating in a research note on Wednesday, July 29th. Finally, Morgan Stanley boosted their price objective on shares of IQVIA from $240.00 to $270.00 and gave the company an “equal weight” rating in a report on Thursday, September 17th. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $294.21.

Institutional Investors Weigh In On IQVIA

Large investors have recently bought and sold shares of the company. BlackRock Inc. purchased a new position in IQVIA during the 2nd quarter worth approximately $2,811,292,000. Dimensional Fund Advisors LP boosted its holdings in shares of IQVIA by 4.2% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,657,696 shares of the medical research company’s stock valued at $282,657,000 after acquiring an additional 66,643 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in shares of IQVIA by 9.0% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,634,264 shares of the medical research company’s stock valued at $315,772,000 after acquiring an additional 134,997 shares during the last quarter. Canada Pension Plan Investment Board acquired a new stake in shares of IQVIA in the second quarter worth $240,911,000. Finally, Bank of America Corp DE acquired a new stake in shares of IQVIA in the second quarter worth $235,551,000. Hedge funds and other institutional investors own 89.62% of the company’s stock.

IQVIA Company Profile

IQVIA Holdings Inc. provides clinical research services, healthcare data and analytics, and technology solutions to pharmaceutical, biotechnology, medical-device, and other healthcare organizations. Its services support the development and commercialization of medicines and other healthcare products. The company’s offerings include clinical trial planning and management, real-world data and evidence, consulting, and software and technology platforms for life sciences research and commercial operations.